Massachusetts Financial Services Co. MA Has $315.19 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Massachusetts Financial Services Co. MA raised its holdings in Natera, Inc. (NASDAQ:NTRA) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,482,818 shares of the medical research company’s stock after buying an additional 85,236 shares during the period. Massachusetts Financial Services Co. MA owned about 2.01% of Natera worth $315,194,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the 2nd quarter worth approximately $28,000. Quarry LP raised its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC lifted its stake in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the period. Finally, Tobam acquired a new position in Natera in the 2nd quarter valued at about $74,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total value of $30,737.92. Following the transaction, the insider now directly owns 111,891 shares of the company’s stock, valued at approximately $13,434,752.37. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,503 shares of company stock worth $6,325,804 in the last 90 days. Insiders own 7.60% of the company’s stock.

Natera Stock Up 0.8 %

NTRA stock opened at $169.20 on Friday. The firm has a 50-day moving average price of $129.84 and a 200-day moving average price of $117.00. Natera, Inc. has a 12 month low of $53.62 and a 12 month high of $171.95. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $22.34 billion, a P/E ratio of -96.14 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.95) earnings per share. As a group, equities research analysts anticipate that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NTRA. Robert W. Baird boosted their price objective on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Piper Sandler upped their price objective on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday. The Goldman Sachs Group lifted their target price on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.